A Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Pembrolizumab and Gemcitabine in Patients With HER2-negative Advanced Breast Cancer (ABC) "PANGEA-Breast"
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Gemcitabine (Primary) ; Pembrolizumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PANGEA; PANGEA-Breast
- 31 Aug 2018 Biomarkers information updated
- 23 Aug 2017 Status changed from not yet recruiting to recruiting.
- 22 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 May 2017.